December 18, 2015.
Isis Pharmaceuticals (Arlsbad, CA) today announced that the company has changed its name to Ionis Pharmaceuticals (pronounced "eye-OH-nis") for obvious reasons.
Lynne Parshall, chief operating officer at Ionis, said: "We decided to change our company name because, when people see or hear our name, we want them to think about the life-saving medicines we are developing."
In conjunction with the corporate name change, the company will trade on the NASDAQ Global Select Market under the new ticker symbol "IONS". In addition, it has a new website address: www.ionispharma.com.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.